Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 July 2022 | Story Leonie Bolleurs | Photo Supplied
Riaz-Seedat
Prof Riaz Seedat, who enrolled for a PhD through the USDP, wishes to create ear, nose, and throat knowledge through his research that is more relevant to the South African setting.

Prof Riaz Seedat is Professor and Head of the Department of Otorhinolaryngology at the University of the Free State (UFS) and in the Free State Department of Health at the Universitas Academic Hospital. It is in this position where he has the opportunity to treat patients, teach students, and conduct research.

As one of the ten academics enrolled in the University Staff Development Programme (USDP), Prof Seedat forms part of the University Capacity Development Programme (UCDP), which seeks to transform academic expertise in the field of global health.

The UFS Office for International Affairs administers the programme, which offers an enriching journey for the group of academics from the University of the Free State (UFS) and the University of Venda (Univen).

In an interview, he revealed the importance of research focused on ENT cases in developing countries. 

How has your background shaped the life and academic path you have chosen? 

During my internship, I had the opportunity to work in ENT. The field sparked great interest in me, so I decided to specialise in it. 

During my training, it became apparent to me that much of the information in the literature was based on research and practices in developed countries and did not reflect the situation in developing countries, where there is a high burden of infectious diseases and presentation of patients with pathology at an advanced stage. My research has been focused on providing a developing country perspective of otorhinolaryngology, particularly with regard to infectious diseases and allergy in the field, creating ENT knowledge that is more relevant to the South African setting. 

What drew you to the USDP project’s call? 

The USDP provides me with the chance to complete my doctorate on recurrent respiratory papillomatosis, a disease that is characterised by recurrent wart-like growths on the surface of the vocal cords or tissue around the vocal cords.

In our context, this affects mostly children and there is a relatively high prevalence of this condition here in the Free State. Research through this PhD will expand knowledge on the diagnosis and management of the condition. 

Please tell us more about your research. 

I have identified that in South Africa, recurrent respiratory papillomatosis, which is caused by the human papillomavirus, occurs more commonly in children than in Europe, where mostly adults are affected. In future, I would like my research to find factors that can help to identify which patients with recurrent respiratory papillomatosis will develop more severe disease, in order to better treat them. 

I have also done work on infectious diseases such as HIV and ENT, describing the impact of HIV in the different ENT conditions we see. 

With regard to allergic rhinitis, we have studied the impact of the condition on patients’ quality of life and are identifying the most frequent allergens present in our setting here in the Free State.

Did the pandemic impact your research?

Yes, it did. Being a full-time clinician for the Free State Department of Health meant that we had to dedicate more time towards managing the pandemic. This has affected patient care and the research we do on the patients. Many patients could not access healthcare facilities because of the lockdown, impacting their treatment, as well as research being carried out. 

Global health is one of the critical issues for the future of the human species, especially in Africa, where both infectious and non-communicable diseases threaten development. What will your project contribute to the field? 

Many of the conditions I am researching are as a result of infectious diseases. Unfortunately, these are conditions that are often neglected as they occur mainly in developing countries. The research will positively impact society through the care and treatment of patients with the condition. 

What are your future career plans? How will a PhD qualification assist you in reaching these goals?

A PhD will help me obtain a better understanding of research content and methodologies. I believe that a PhD will also equip me with the knowledge to better supervise individuals who wish to further their academic careers and do their own PhDs. 

What is your advice for aspiring PhD candidates?

I would advise someone who wishes to complete a PhD to work on a topic that they have a great interest in, because it is a task that will take much of your time. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept